Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology

Medical Hypotheses

Volumn 73, Issue 5, 2009, Pages 770-780

  Csoka, Antonei B ^a   Szyf, Moshe ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; CHLOROQUINE; COLCHICINE DERIVATIVE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; FLUOXETINE; HOMOCYSTEINE; HYDRALAZINE; HYDROXYUREA; IMIPRAMINE; ISOTRETINOIN; METHOTREXATE; METHYLPHENIDATE; NALIDIXIC ACID; NARCOTIC AGENT; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PROCAINAMIDE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE BINDING PROTEIN; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VINBLASTINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACNE; AMNESIA; ARTICLE; ATTENTION DEFICIT DISORDER; BREAST CANCER; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE MODEL; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; DRUG MEGADOSE; EMBRYOTOXICITY; EPIGENETICS; FETOTOXICITY; FUZZY SYSTEM; GENE EXPRESSION; GENETIC REGULATION; GENETIC VARIABILITY; GENOMICS; HEART DISEASE; HEMOSTASIS; HUMAN; HYPERTENSION; INFERTILITY; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; METAGENOMICS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OBESITY; OVARY CANCER; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; TARDIVE DYSKINESIA; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 70349751583     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.10.039     Document Type: Article

References (185)

1. Bird A. Perceptions of epigenetics. Nature 447 (2007) 396-398
2. Waddington C.H. The epigenotype. Endeavour 1 (1942) 18-20
3. Holliday R. Mechanisms for the control of gene activity during development. Biol Rev Cambr Philos Soc 65 (1990) 431-471
4. Russo V.E.A., Martienssen R.A., and Riggs A.D. Epigenetic mechanisms of gene regulation (1996), Cold Spring Harbor Laboratory Press, Plainview, NY
5. Whitelaw N.C., and Whitelaw E. Transgenerational epigenetic inheritance in health and disease. Curr Opin Genet Dev 18 (2008) 273-279
6. Liu L., Li Y., and Tollefsbol T.O. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 10 (2008) 25-36
7. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447 (2007) 425-432
8. Surani M.A., Hayashi K., and Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 128 (2007) 747-762
9. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet 2006;15 (Spec No 1):R95-101.
10. Weinhold B. Epigenetics: the science of change. Environ Health Perspect 114 (2006) A160-A167
11. Whitelaw N.C., and Whitelaw E. How lifetimes shape epigenotype within and across generations. Hum Mol Genet 15 (2006) R131-R137
12. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 447 (2007) 433-440
13. Feinberg A.P. Epigenetics at the epicenter of modern medicine. JAMA 299 (2008) 1345-1350
14. Szutorisz H., and Dillon N. The epigenetic basis for embryonic stem cell pluripotency. Bioessays 27 (2005) 1286-1293
15. Dinnyes A., Tian X.C., and Yang X. Epigenetic regulation of foetal development in nuclear transfer animal models. Reprod Domest Anim 43 Suppl. 2 (2008) 302-309
16. Zhao R., and Daley G.Q. From fibroblasts to iPS cells: induced pluripotency by defined factors. J Cell Biochem 105 (2008) 949-955
17. Fraga M.F., and Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 23 (2007) 413-418
18. Pál C., and Miklós I. Epigenetic inheritance, genetic assimilation and speciation. J Theor Biol 200 (1999) 19-37
19. Lukens L.N., and Zhan S. The plant genome's methylation status and response to stress: implications for plant improvement. Curr Opin Plant Biol 10 (2007) 317-322
20. Gräff J., and Mansuy I.M. Epigenetic codes in cognition and behaviour. Behav Brain Res 192 (2008) 70-87
21. Tsankova N., Renthal W., Kumar A., and Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8 (2007) 355-367
22. Stöger R. The thrifty epigenotype: an acquired and heritable predisposition for obesity and diabetes?. Bioessays 30 (2008) 156-166
23. Houshdaran S., Cortessis V.K., Siegmund K., Yang A., Laird P.W., and Sokol R.Z. Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS ONE 2 (2007) e1289
24. Gouvêa T.S., Morimoto H.K., de Faria M.J., Moreira E.G., and Gerardin D.C. Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. Pharmacol Biochem Behav 90 (2008) 416-419
25. Delage B., and Dashwood R.H. Dietary manipulation of histone structure and function. Annu Rev Nutr 28 (2008) 347-366
26. Szyf M., McGowan P., and Meaney M.J. The social environment and the epigenome. Environ Mol Mutagen 49 (2008) 46-60
27. Szyf M., Weaver I., and Meaney M. Maternal care, the epigenome and phenotypic differences in behavior. Reprod Toxicol 24 (2007) 9-19
28. Lipton BH. The Biology of belief: Unleashing the power of consciousness, Matter and miracles. Mountain of love; 2005.
29. Church D. The genie in your genes: epigenetic medicine and the new biology of intention. Elite Books; 2007.
30. Dolinoy D.C., and Jirtle R.L. Environmental epigenomics in human health and disease. Environ Mol Mutagen 49 (2008) 4-8
31. Vineis P. Methodological insights: fuzzy sets in medicine. J Epidemiol Community Health 62 (2008) 273-278
32. Sadegh-Zadeh K. Fuzzy health, illness, and disease. J Med Philos 25 (2000) 605-638
33. Seising R. From vagueness in medical thought to the foundations of fuzzy reasoning in medical diagnosis. Artif Intell Med 38 (2006) 237-256
34. Loscalzo J., Kohane I., and Barabasi A.L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 3 (2007) 124
35. Butcher L.M., and Beck S. Future impact of integrated high-throughput methylome analyses on human health and disease. J Genet Genomics 35 (2008) 391-401
36. Hatchwell E., and Greally J.M. The potential role of epigenomic dysregulation in complex human disease. Trends Genet 23 (2007) 588-595
37. Ptak C., and Petronis A. Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Pharmacol Toxicol 48 (2008) 257-276
38. Baranzini SE. Systems-based medicine approaches to understand and treat complex diseases. Autoimmunity 2006;39:651-62.
39. Bland J. Functional somatic syndromes, stress pathologies, and epigenetics. Altern Ther Health Med 14 (2008) 14-16
40. Chuang J.C., and Jones P.A. Epigenetics and microRNAs. Pediatr Res 61 (2007) 24R-29R
41. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140 (1988) 2197-2200
42. Zhou Y., and Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 7 (2008) 376-383
43. Richardson B. Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol 3 (2007) 521-527
44. Gómez-Puerta J.A., Burlingame R.W., and Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 7 (2008) 606-611
45. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., and Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 18 (1991) 530-534
46. Lee B.H., Yegnasubramanian S., Lin X., and Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase. J Biol Chem 280 (2005) 40749-40756
47. Arce C., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Candelaria M., and Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Trans Med 4 (2006) 10
48. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
49. Detich N., Bovenzi V., and Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 278 (2003) 27586-27592
50. Milutinovic S., D'Alessio A.C., Detich N., and Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 28 (2007) 560-571
51. Lee M.H., Hong I., Kim M., et al. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol 220 (2007) 45-59
52. Massa V., Cabrera R.M., Menegola E., Giavini E., and Finnell R.H. Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet Genomics 15 (2005) 787-800
53. Nagai K., Natori T., Nishino T., and Kodaira F. Epigenetic disregulation induces cell growth retardation in primary cultured glial cells. J Biosci Bioeng 105 (2008) 470-475
54. Hessen E., Lossius M.I., Reinvang I., and Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 47 (2006) 2038-2045
55. Chen Z., Karaplis A.C., Ackerman S.L., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 10 (2001) 433-443
56. Friso S., Choi S.W., Girelli D., et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99 (2002) 5606-5611
57. Stern L.L., Mason J.B., Selhub J., and Choi S.W. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidem Biomark Prev 9 (2000) 849-853
58. Heijmans B.T., Boer J.M., Suchiman H.E., et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 63 (2003) 1249-1253
59. Toffoli G., Russo A., Innocenti F., et al. Effect of methylenetetrahydrofolate reductase 677C- ->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103 (2003) 294-299
60. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007;16 (Spec No 1):R50-9.
61. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 49 (1989) 5829-5836
62. Nyce J., Leonard S., Canupp D., Schulz S., and Wong S. Epigenetic mechanisms of drug resistance. drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 90 (1993) 2960-2964
63. Holliday R. The possibility of epigenetic transmission of defects induced by teratogens. Mutat Res 422 (1998) 203-205
64. McBride WG. Teratogenic action of drugs. Med J Aust 1963; 2: 6659-98.
65. McBride WG. Thalidomide may be a mutagen. Brit Med J 1994; 308: 1635-6.
66. Ashby J., Tinwell H., Callander R.D., Kimber I., Clau P., Galloway S.M., et al. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutation Res. 396 (1997) 45-64
67. Huang P.H.T., and McBride W.G. Thalidomide induced alteration in secondary structure of rat embryonic DNA in vivo. Teratog Carcinog Mutag 10 (1990) 281-294
68. Huang P.H.T., and McBride W.G. Interaction of wglutarimide-2-14Cx thalidomide with rat embryonic DNA in vivo. Teratog Carcinog Mutag 17 (1997) 1-5
69. Bérard A., Azoulay L., Koren G., Blais L., Perreault S., and Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 63 (2007) 196-205
70. Balmer J.E., and Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 43 (2002) 1773-1808
71. Mehta K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 17 (2003) 1-12
72. Kuriyama M., Udagawa A., Yoshimoto S., et al. DNA methylation changes during cleft palate formation induced by retinoic acid in mice. Cleft Palate Craniofac J 45 (2008) 545-551
73. Sadick N.S. A practitioner's 10-year experience with isotretinoin and side effect profiles. Int J Cosmet Surg Aesthet Dermatol 4 (2002) 89-94
74. Archer C.B., Elias P.M., Lowe N.J., and Griffiths W.A. Extensive spinal hyperostosis in a patient receiving isotretinoin-progression after 4 years of etretinate therapy. Clin Exp Dermatol 14 (1989) 319-321
75. Mollan S.P., Woodcock M., Siddiqi R., Huntbach J., Good P., and Scott R.A. Does use of isotretinoin rule out a career in flying?. Br J Ophthalmol 90 (2006) 957-959
76. Ellies P., Dighiero P., Legeais J.M., Pouliquen Y.J., and Renard G. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea 19 (2000) 238-239
77. Reddy D., Siegel C.A., Sands B.E., and Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol 101 (2006) 1569-1573
78. Passier J.L., Srivastava N., and van Puijenbroek E.P. Isotretinoin-induced inflammatory bowel disease. Neth J Med 64 (2006) 52-54
79. Rubenstein R., Roenigk Jr. H.H., Stegman S.J., and Hanke C.W. Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 15 (1986) 280-285
80. Milstone A.M., and Milstone L.M. Is retinoid-induced osteopenia reversible?. Arch Dermatol 138 (2002) 1516-1517
81. Zane L.T., Leyden W.A., Marqueling A.L., and Manos M.M. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 142 (2006) 1016-1022
82. Tirado Sánchez A., and León Dorantes G. Erectile dysfunction during isotretinoin therapy. Actas Urol Esp 29 (2005) 974-976
83. O'Reilly K., Bailey S.J., and Lane M.A. Retinoid-mediated regulation of mood: possible cellular mechanisms. Exp Biol Med (Maywood) 233 (2008) 251-258
84. Bremner J.D., Fani N., Ashraf A., et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 162 (2005) 983-991
85. Ooi L., and Wood I.C. Regulation of gene expression in the nervous system. Biochem J 414 (2008) 327-341
86. Paulson G.W. Historical comments on tardive dyskinesia: a neurologist's perspective. J Clin Psychiatry 66 (2005) 260-264
87. Rupniak M.N., Jenner P., and Marsden C.D. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci 32 (1983) 2289-2311
88. Hoerger M. The primacy of neuroleptic-induced D2 receptor hypersensitivity in tardive dyskinesia. Psychiatry Online 13 (2007) 18-26
89. Cheng M.C., Liao D.L., Hsiung C.A., Chen C.Y., Liao Y.C., and Chen C.H. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 11 (2008) 207-216
90. Chen M.L., and Chen C.H. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology 30 (2005) 268-277
91. Fatemi S.H., Reutiman T.J., Folsom T.D., et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 31 (2006) 1888-1899
92. Scheen A.J., and De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33 (2007) 169-175
93. Haupt D.W., and Newcomer J.W. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62 Suppl 27 (2001) 15-26
94. El-Osta A., Brasacchio D., Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205 (2008) 2409-2417
95. Renthal W., and Nestler E.J. Epigenetic mechanisms in drug addiction. Trends Mol Med 14 (2008) 341-350
96. McClung C.A., and Nestler E.J. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 33 (2008) 3-17
97. Yano M., and Steiner H. Methylphenidate and cocaine: the same effects on gene regulation?. Trends Pharmacol Sci 28 (2007) 588-596
98. Brandon C.L., and Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur J Neurosci 18 (2003) 1584-1592
99. Adriani W., Leo D., Guarino M., et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann N Y Acad Sci 1074 (2006) 52-73
100. Adriani W., Leo D., Greco D., et al. Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 31 (2006) 1946-1956
101. Carlezon Jr. W.A., Mague S.D., and Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 54 (2003) 1330-1337
102. Mague S.D., Andersen S.L., and Carlezon Jr. W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 57 (2005) 120-125
103. Bolaños C.A., Barrot M., Berton O., Wallace-Black D., and Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 54 (2003) 1317-1329
104. Hansen H.H., and Mikkelsen J.D. Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 352 (1998) 307-315
105. Raap D.K., Garcia F., Muma N.A., Wolf W.A., Battaglia G., and van de Kar L.D. Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins. J Pharmacol Exp Ther 288 (1999) 561-567
106. Faure C., Ouissame M.F., and Nasser H. Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 6 (2006) 235-245
107. Palotas M., Palotas A., Puskas L.G., Kitajka K., Pakaski M., Janka Z., et al. Gene expression profile analysis of the rat cortex following treatment with imipramine and citalopram. Int J Neuropsychopharmacol 7 (2004) 401-413
108. Kalman J., Palotas A., Juhasz A., Rimanoczy A., Hugyecz M., Kovacs Z., et al. Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression-evolution of antidepressants and the role of the "neuro-immune" system. Neurochem Res 30 (2005) 1429-1438
109. Yamada M., Yamada M., and Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 999-1009
110. Boehm C., Newrzella D., Herberger S., Schramm N., Eisenhardt G., Schenk V., et al. Effects of antidepressant treatment on gene expression profile in mouse brain: cell type-specific transcription profiling using laser microdissection and microarray analysis. J Neurochem 97 Suppl 1 (2006) 44-49
111. Hyman S.E. Even chromatin gets the blues. Nat Neurosci 9 (2006) 465-466
112. Newton S.S., and Duman R.S. Chromatin remodeling: a novel mechanism of psychotropic drug action (relates to article by Cassel, et al. fastforward 2 May 2006). Mol Pharmacol 70 (2006) 440-443
113. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., and Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9 (2006) 519-525
114. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J.B., et al. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol 70 (2006) 487-492
115. Cohen AJ. Antidepressant-induced sexual dysfunction associated with low serum free testosterone. Psychiatry Online; 1999.
116. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. Urology 2007;69:185.e5-7.
117. Csoka A.B., and Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom 75 (2006) 187-188
118. Bolton J.M., Sareen J., and Reiss J.P. Genital anaesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther 32 (2006) 327-330
119. Kauffman R.P., and Murdock A. Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypical antidepressant nefazodone. The Open Women's Health J 1 (2007) 1-3
120. Csoka A.B., Bahrick A.S., and Mehtonen O.-.P. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Sex Med 5 (2008) 227-233
121. Ferguson R.J., and Ahles T.A. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 3 (2003) 215-222
122. Ahles T.A., Saykin A.J., Furstenberg C.T., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20 (2002) 485-493
123. Dietrich J., Han R., Yang Y., Mayer-Pröschel M., and Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5 (2006) 22
124. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Pröschel M., and Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7 (2008) 12
125. Freim Wahl S.G., Folvik M.R., and Torp S.H. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26 (2007) 68-73
126. Caǧlar K., Varan A., Akyüz C., et al. Second neoplasms in pediatric patients treated for cancer: a center's 30-year experience. J Pediatr Hematol Oncol 28 (2006) 374-378
127. Pogribny I.P., Rusyn I., and Beland F.A. Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ Mol Mutagen 49 (2008) 9-15
128. Pogribny I.P., Bagnyukova T.V., Tryndyak V.P., et al. Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesis. Toxicol Appl Pharmacol 225 (2007) 61-69
129. Badia E., Duchesne M.J., Nicolas J.C., and Pons M. Rapid tamoxifen-induced inactivation of an estrogenic response is accompanied by a localized epigenetic modification but not by mutations. Breast Cancer Res Treat 47 (1998) 71-81
130. Badia E., Duchesne M.J., Semlali A., et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 60 (2000) 4130-4138
131. Pogribny I.P., Tryndyak V.P., Boyko A., Rodriguez-Juarez R., Beland F.A., and Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619 (2007) 30-37
132. Sanders R.D., Xu J., Shu Y., Fidalgo A., Ma D., and Maze M. General anesthetics induce apoptotic neurodegeneration in the neonatal rat spinal cord. Anesth Analg 106 (2008) 1708-1711
133. Xie Z., Dong Y., Maeda U., et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci 27 (2007) 1247-1254
134. Yang H., Liang G., Hawkins B.J., Madesh M., Pierwola A., and Wei H. Inhalational anesthetics induce cell damage by disruption of intracellular calcium homeostasis with different potencies. Anesthesiology 109 (2008) 243-250
135. Caza N., Taha R., Qi Y., and Blaise G. The effects of surgery and anesthesia on memory and cognition. Prog Brain Res 169 (2008) 409-422
136. Eckenhoff R.G., Johansson J.S., Wei H., et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 101 (2004) 703-709
137. Lee T.A., Wolozin B., Weiss K.B., and Bednar M.M. Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 7 (2005) 319-324
138. Pan J.Z., Wei H., Hecker J.G., Tobias J.W., Eckenhoff R.G., and Eckenhoff M.F. Rat brain DNA transcript profile of halothane and isoflurane exposure. Pharmacogenet Genomics 16 (2006) 171-182
139. Rampil I.J., Moller D.H., and Bell A.H. Isoflurane modulates genomic expression in rat amygdala. Anesth Analg 102 (2006) 1431-1438
140. Pan J.Z., Xi J., Eckenhoff M.F., and Eckenhoff R.G. Inhaled anesthetics elicit region-specific changes in protein expression in mammalian brain. Proteomics 8 (2008) 2983-2992
141. Culley D.J., Yukhananov R.Y., Xie Z., Gali R.R., Tanzi R.E., and Crosby G. Altered hippocampal gene expression 2 days after general anesthesia in rats. Eur J Pharmacol 549 (2006) 71-78
142. Giusti R.M., Iwamoto K., and Hatch E.E. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Int Med 122 (1995) 778-788
143. Adam E., Decker D.G., Herbst A.L., Noller K.L., Tilley B.C., and Townsend D.E. Vaginal and cervical cancers and other abnormalities associated with exposure in utero to diethylstilbestrol and related synthetic hormones. Cancer Res 37 (1977) 1249-1251
144. Herbst A.L., Ulfelder H., and Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284 (1971) 878-881
145. Walker B.E., and Haven M.I. Intensity of multigenerational carcinogenesis from diethylstilbestrol in mice. Carcinogenesis 18 (1997) 791-793
146. Sato K., Fukata H., Kogo Y., Ohgane J., Shiota K., and Mori C. Neonatal exposure to diethylstilbestrol alters the expression of DNA methyltransferases and methylation of genomic DNA in the epididymis of mice. Endocr J 53 (2006) 331-337
147. Kangaspeska S., Stride B., Métivier R., et al. Transient cyclical methylation of promoter DNA. Nature 452 (2008) 112-115
148. Kahlenborn C., Modugno F., Potter D.M., and Severs W.B. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 81 (2006) 1290-1302
149. Pitts S.A., and Emans S.J. Controversies in contraception. Curr Opin Pediatr 20 (2008) 383-389
150. Warnock J.K., Clayton A., Croft H., Segraves R., and Biggs F.C. Comparison of androgens in women with hypoactive sexual desire disorder: those on combined oral contraceptives (COCs) vs. Those not on COCs. J Sex Med 3 (2006) 878-882
151. Panzer C., Wise S., Fantini G., Kang D., Munarriz R., Guay A., et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med 3 (2006) 104-113
152. Rusquet R., Bonhommet M., and David J.C. Quinolone antibiotics inhibit eucaryotic DNA polymerase alpha and beta, terminal deoxynucleotidyl transferase but not DNA ligase. Biochem Biophys Res Commun 121 (1984) 762-769
153. Forsgren A., Schlossman S.F., and Tedder T.F. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 31 (1987) 768-773
154. Gootz T.D., Barrett J.F., and Sutcliffe J.A. Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrob Agents Chemother 34 (1990) 8-12
155. Mehlhorn A.J., and Brown D.A. Safety concerns with fluoroquinolones. Ann Pharmacother 41 (2007) 1859-1866
156. Cohen J.S. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 35 (2001) 1540-1547
157. McGarvey W.C., Singh D., and Trevino S.G. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 17 (1996) 496-498
158. Goto K., Yabe K., Suzuki T., Takasuna K., Jindo T., and Manabe S. Gene expression profiles in the articular cartilage of juvenile rats receiving the quinolone antibacterial agent ofloxacin. Toxicology 249 (2008) 204-213
159. Clark D.W., Layton D., Wilton L.V., Pearce G.L., and Shakir S.A. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the drug safety research unit prescription-event monitoring database. Drug Saf 24 (2001) 1143-1154
160. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008;117:2706-15.
161. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24 (2006) 3-10
162. Alderman M.H. New onset diabetes during antihypertensive therapy. Am J Hypertens 21 (2008) 493-499
163. Sirtori C.R. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res 22 (1990) 555-563
164. Tiwari A., Bansal V., Chugh A., and Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 5 (2006) 651-666
165. Kato N., Liang Y.Q., Ochiai Y., and Jesmin S. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin. Eur J Pharmacol 584 (2008) 376-389
166. Hanai J., Cao P., Tanksale P., et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117 (2007) 3940-3951
167. Buettner C., and Lecker S.H. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics 9 (2008) 1133-1142
168. Sirvent P., Mercier J., and Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8 (2008) 333-338
169. Hilário M.O., Terreri M.T., and Len C.A. Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors. J Pediatr (Rio J) 82 5 Suppl (2006) S206-S212
170. Merck: "APPROVe off-drug extension: preliminary analyses of thrombotic cardiovascular safety". News release, Merck. Thomson Street Events, Conference call transcript, May 11; 2006.
171. Wang X.M., Wu T.X., Hamza M., Ramsay E.S., Wahl S.M., and Dionne R.A. Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain 128 (2007) 136-147
172. Wang X.M., Wu T.X., Lee Y.S., and Dionne R.A. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther 79 (2006) 303-315
173. Pache R.A., Zanzoni A., Naval J., Mas J.M., and Aloy P. Towards a molecular characterisation of pathological pathways. FEBS Lett 582 (2008) 1259-1265
174. Saluz H.P., Feavers I.M., Jiricny J., and Jost J.P. Genomic sequencing and in vivo foot-printing of an expression specific hypersensitive site of avian vitellogenin II promoter reveals demethylation of a mCpG and a change in specific interaction of proteins with DNA. Proc Natl Adac Sci USA 85 (1988) 6697-6700
175. Tsay G.J., and Zouali M. Toxicogenomics - a novel opportunity to probe lupus susceptibility and pathogenesis. Int Immunopharmacol 8 (2008) 1330-1337
176. Sha K. A mechanistic view of genomic imprinting. Annu Rev Genomics Hum Genet 9 (2008) 197-216
177. Kelsey G. Genomic imprinting-roles and regulation in development. Endocr Dev 12 (2007) 99-112
178. Horsthemke B., and Wagstaff J. Mechanisms of imprinting of the Prader-Willi/Angelman region. Am J Med Genet A 146A (2008) 2041-2052
179. Kaati G., Bygren L.O., and Edvinsson S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet 10 (2002) 682-688
180. Pembrey M.E. Time to take epigenetic inheritance seriously. Eur J Hum Genet 10 (2002) 669-671
181. Gouvêa TS, Morimoto HK, de Faria MJ, Moreira EG, Gerardin DC. Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. Pharmacol Biochem Behav; 2008.
182. Yamamoto M., Tase N., Okuno T., et al. Monitoring of gene expression in differentiation of embryoid bodies from cynomolgus monkey embryonic stem cells in the presence of bisphenol A. J Toxicol Sci 32 (2007) 301-310
183. Mehta A., Konala V.B., Khanna A., and Majumdar A.S. Assessment of drug induced developmental toxicity using human embryonic stem cells. Cell Biol Int 32 (2008) 1412-1424
184. Blaheta R.A., and Cinatl Jr. J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22 (2002) 492-511
185. Segura-Pacheco B., Trejo-Becerril C., and Perez-Cardenas E. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9 (2003) 1596-1603